Private Advisor Group LLC Acquires 5,437 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Private Advisor Group LLC grew its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 238.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,716 shares of the specialty pharmaceutical company’s stock after purchasing an additional 5,437 shares during the quarter. Private Advisor Group LLC’s holdings in Jazz Pharmaceuticals were worth $860,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Versant Capital Management Inc increased its position in Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in Jazz Pharmaceuticals during the second quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 97 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new position in Jazz Pharmaceuticals during the 2nd quarter valued at about $33,000. 89.14% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on JAZZ. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Royal Bank of Canada upped their price objective on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, October 23rd. Morgan Stanley reduced their price objective on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research note on Friday, July 12th. HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Finally, Wells Fargo & Company cut their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $173.43.

Jazz Pharmaceuticals Stock Up 0.4 %

Shares of NASDAQ:JAZZ opened at $110.45 on Friday. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.48. The business has a 50 day simple moving average of $110.68 and a two-hundred day simple moving average of $109.56. The firm has a market capitalization of $6.82 billion, a PE ratio of 18.98, a price-to-earnings-growth ratio of 1.38 and a beta of 0.57. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. On average, equities analysts predict that Jazz Pharmaceuticals plc will post 16.02 EPS for the current year.

Insider Buying and Selling

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.